Skip to main content

Kayvon Modjarrad, MD, PhD

Director, Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research

Loading Presentations
Kayvon Modjarrad, MD, PhD

Dr. Modjarrad is an infectious diseases physician and vaccine scientist who is the director of the Emerging Infectious Diseases Branch at the Walter Reed Army Institute of Research and an associate professor of medicine at the Uniformed Services University of Health Sciences. Dr. Modjarrad has led efforts to develop, test, and advance vaccine candidates against multiple pathogens of global importance, including HIV, RSV, Ebola, MERS-CoV, and Zika. In 2015, Dr. Modjarrad was on assignment from the US government to the World Health Organization to assist with the response to the West African Ebola Outbreak. Specifically, he coordinated the multiple phase 1 trials of VSV-ZEBOV.

Prior to this assignment, Dr. Modjarrad served as the head of the Viral Pathogenesis Translational Science Core at the National Institutes of Health Vaccine Research Center, where he also completed his infectious diseases fellowship and still holds a position as an advisory scientist. In his current capacity, he is the principal investigator of the first-in-human MERS-CoV vaccine trial and a protocol co-chair of a multi-site phase 2 Ebola vaccine trial. Dr. Modjarrad is the head of the US Army’s Zika Vaccine Program.

He has more than 60 peer-reviewed publications in high-impact journals, and has served as the principal editor for two textbooks, most recently one on emerging vaccine technologies. Dr. Modjarrad is also a member of the 2020 Annual Conference on Vaccinology Research planning committee.

Kayvon Modjarrad, MD, PhD Presentations

  • June 18, 2020 at 10:00 AM - 11:15 AM

    Vaccine Development for Novel Coronavirus Response

    The spread of SARS-CoV-2 and the resulting COVID-19 pandemic has had wide-reaching effects that require a multifaceted response. Accelerating vaccine development and distribution is a key component in responding to this emerging pathogen. Vaccine development typically takes decades from research and development to implementation, so having licensed and approved vaccines available for mass distribution in a 12-18 month timeframe would...

    Read More
+ Export Events